Market Overview

Presbia Announces New Management Appointments

Share:

Presbia PLC (NASDAQ:LENS, or the "Company")), an ophthalmic device
company and leader in near-vision restoration, announced that Casey Lind
has been appointed as Chief Operating Officer effective February 12,
2018. As Chief Operating Officer, Ms. Lind is responsible for the
Company's manufacturing, engineering, quality and IT departments. Ms.
Lind brings over 30 years of experience, including 29 years at Alcon
where she was in senior leadership positions across manufacturing,
global supply chain, and research & development. Ms. Lind has numerous
issued patents ranging from drug delivery and injection control of
manufacturing processes for phase transition drug formulations. Ms. Lind
also has an active role at both the national and local levels in
Ophthalmic World Leaders (OWL). Ms. Lind is a graduate of Iowa State
University, with a degree in Business, and received her MBA from Webster
University.

In addition, the Company announced that Dr. Magda Michna, PhD will
become Chief Clinical Officer, also effective February 12, 2018. Dr.
Michna will increase her responsibility overseeing clinical affairs to
also include the Company's medical affairs and regulatory functions. Dr.
Michna joined the Company in February 2017 as VP of Clinical Affairs,
bringing more than 12 years of experience in ophthalmic clinical
research and development. Prior to Presbia, Dr. Michna worked at Alcon,
Johnson & Johnson Vision, and in academic research at the McGill
University School of Ophthalmology.

"We have assembled a leading ophthalmic management team at Presbia,"
said Mark Yung, Chairman and CEO of Presbia. "I am looking forward to
working with Casey and Magda, given their extensive ophthalmic
experience, and the rest of the team to advance the Flexivue Microlens™
as an FDA-approved optical lens implant that is available to the global
presbyopia market."

Forward-Looking Statements

This release contains "forward-looking statements" made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Information provided and statements contained in this press
release that are not purely historical are forward-looking statements.
These statements are typically preceded by words such as "believes,"
"expects," "anticipates," "intends," "will," "may," "should," or similar
expressions. Such forward-looking statements only speak as of the date
of this press release and Presbia assumes no obligation to update the
information included in this press release. Statements made in this
press release that are forward-looking in nature may involve risks and
uncertainties, including, but not limited to, the factors listed under
"Risk Factors" in our annual report on Form 10-K for the year ended
December 31, 2016, quarterly reports on Form 10-Q, and other reports
that Presbia files with the SEC. Accordingly, readers are cautioned that
any such forward-looking statements are not guarantees and are subject
to certain risks, uncertainties and assumptions that are difficult to
predict. Although Presbia believes that the expectations reflected in
such forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements. Unless
otherwise required by law, Presbia also disclaims any obligation to
update its view of any such risks or uncertainties or to announce
publicly the result of any revisions to the forward-looking statements
made in this press release.

About Presbia

Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has
developed and is currently marketing the
presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that
is implanted in a corneal pocket created by a femtosecond laser. The
Presbia Flexivue Microlens™ has received a CE mark for the European
Economic Area, allowing the lens to be marketed in over 30 countries
across Europe. A staged pivotal U.S. clinical trial for the Presbia
Flexivue Microlens™ commenced in 2014.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com